A definitive randomized controlled trial of 738 patients with chronic obstructive pulmonary disease (COPD) and moderate resting hypoxemia (resting oxygen saturation 89-93%) found no benefit of long-term supplemental oxygen therapy on survival, COPD-related hospitalization, or disease-specific quality of life compared to no supplemental oxygen — a finding that challenges widespread clinical practice and has already prompted guideline revision discussions.
Background: The Home Oxygen Evidence Base
Long-term oxygen therapy (LTOT) is well-established for patients with severe resting hypoxemia (SpO₂ ≤88% or PaO₂ ≤55 mmHg), where two landmark trials from the 1980s — the MRC and NOTT studies — demonstrated survival benefit. However, patients with moderate hypoxemia (SpO₂ 89-93%) represent a much larger clinical population and have been prescribed supplemental oxygen based on extrapolation from the severe hypoxemia trials rather than direct evidence.
The LOTT-2 Trial
The Long-Term Oxygen Treatment Trial 2 (LOTT-2) enrolled 738 COPD patients with moderate resting hypoxemia at 42 centers. Patients were randomized to supplemental oxygen 24 hours/day or no supplemental oxygen and followed for a minimum of 12 months (median 18.4 months).
Results
The primary composite endpoint — time to death or first hospitalization for any cause — did not differ between groups (HR 0.94, 95% CI 0.79-1.12, p=0.49). Secondary endpoints including COPD-specific hospitalizations, 6-minute walk distance, lung function (FEV₁), self-reported dyspnea, and health-related quality of life (SGRQ) also showed no significant difference.
Notably, supplemental oxygen did not improve sleep quality, cognitive function, or exercise tolerance in any subgroup analysis, including those with significant nocturnal desaturation.
Implications for Clinical Practice
Approximately 1.5 million Americans with COPD receive home supplemental oxygen prescriptions at a cost of $2.5 billion annually to Medicare alone. These data suggest that a substantial proportion — specifically those with moderate rather than severe hypoxemia — may be receiving oxygen therapy without clinical benefit.
“These findings should prompt a frank conversation with patients currently receiving supplemental oxygen for moderate hypoxemia,” said lead author Dr. Richard Casaburi of UCLA. “Continuing therapy in patients who prefer it is reasonable, but new prescriptions should be evidence-based.”
Guideline Revisions Expected
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) is reviewing these data and is expected to update LTOT recommendations at its 2027 report, likely removing supplemental oxygen as a standard recommendation for moderate (vs severe) resting hypoxemia.
Leave a Reply